In animal models, TMAO has been shown to induce T2D via increasing fasting insulin levels and insulin resistance (HOMA-IR), aggravating impaired glucose tolerance [8,9], inducing adipose tissue inflammation, and obstructing the hepatic insulin signalling pathway [8]. The gene discussed is INS; the disease is Impaired glucose tolerance.